

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in this application:

Listing of Claims:

Claims 1 (currently amended): A product packaging system for preventing degradation of a drug in a carrier composition of a transdermal delivery system, consisting essentially of:

(a) a product package substantially moisture impermeable comprising a thermoplastic material configured in the shape of a container having one opening, and further having a substantially moisture impermeable cover sheet comprising a thermoplastic material coextensive to said container opening and affixed to the opening edges by means of heat or adhesive;

(b) one or more child-resistant pouches which are preferentially permeable to moisture consisting essentially of:

(i) a primary layer of a nitrile rubber modified acrylonitrile-methyl acrylate copolymer, and

(ii) a secondary layer of polyester affixed to said primary layer by means of heat or an adhesive;

(iii) [[a]] one or more transdermal systems comprising a therapeutically effective amount of methylphenidate in a non-aqueous carrier composition, [[said]] the one or more transdermal systems being sealed within [[a]] the one or more child-resistant pouches;

(c) a desiccant capable of absorbing at least 1.5 grams of moisture over a one year period of storage,

wherein the one or more child-resistant pouches and desiccant are sealed within the product package.

Claims 2 – 13 (canceled).

Claim 14 (new): A product packaging system for preventing degradation of a drug in a carrier composition of a transdermal delivery system, comprising:

(a) a sealable product package substantially moisture impermeable comprising a barrier material configured to define a space to contain and surround one or more pouches and a desiccant;

(b) one or more child-resistant pouches which are self-sealing and preferentially permeable to moisture consisting essentially of:

(i) a primary layer of a nitrile rubber modified acrylonitrile-methyl acrylate copolymer; and

(ii) a secondary layer of polyester,

(iii) one or more transdermal systems comprising a therapeutically effective amount of a drug in a non-aqueous carrier composition, the one or more transdermal systems being sealed within the one or more child-resistant pouches; and

(c) a desiccant,

wherein the one or more pouches and desiccant are sealed within the product package.

Claim 15 (new): A product packaging system according to claim 14, wherein the one or more transdermal systems comprise a chiral drug.

Claim 16 (new): A product packaging system according to claim 15, wherein the chiral drug is methylphenidate.